5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Alkem Laboratories Ltd.

•
alkemlabs.comBSE: 539523NSE: ALKEM
Market Cap₹ 60,853 Cr.
Current Price
High / Low₹ 5,934 / 5,051
Stock P/E28.2
Book Value₹ 1,197
Price to Book4.60
Dividend Yield1.04 %
ROCE21.3 %
ROE18.3 %
Face Value₹ 2

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2016 • Pharma Business: 100.0%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company has a healthy return on capital (ROCE) of 20.8%
  • Company has consistently been profitable over the last 5 years
  • Operating margins have improved to 13.3% from 10.2%
  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 0.91x)
  • Company has a consistent dividend-paying track record
  • Company comfortably covers its interest (18.9x coverage)

CONS

  • Promoter holding has decreased over last 2 years: -6.7pp
  • Total debt has risen sharply - up 52.8% year on year
  • Company has delivered a poor profit growth of 7.8% over past five years
  • Recurring exceptional / one-off items are inflating headline profit

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY PHARMANIFTYLARGEMIDCAP250NIFTYMIDCAP150NIFTY MIDCAP 100NIFTY MIDCAP 150
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.ALKEM5089.5028.2160852.611.04520.98-22.003740.1510.9521.2820.47
Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
2,9683,4403,3242,9363,0323,4153,3743,1443,3714,0013,7373,6033,740
2,5792,6932,6162,5342,4232,6622,6152,7522,6323,0802,9093,0863,121
Operating Profit389747708402609753759391739921828517619
OPM %13.11%21.71%21.29%13.69%20.08%22.05%22.51%12.45%21.92%23.01%22.16%14.36%16.56%
6664276120134931461491049065153
Interest30302527292836283035425447
Depreciation72747083807985112889495106100
Profit before Tax353648655367619780731396771896781423771
Tax %18.43%5.12%7.73%17.11%11.16%10.04%12.35%18.50%13.32%12.97%16.34%40.48%32.47%
Net Profit0000550702641322668779653251521
23.9851.9049.7624.5545.6057.6052.3425.5755.5663.9953.1919.7743.49

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
5,6886,3927,3578,3448,86510,63411,59912,66812,96514,71215,081
4,6895,3836,2426,8716,9238,5819,99010,42210,45211,71812,196
Operating Profit9991,0091,1151,4731,9422,0531,6092,2452,5122,9942,885
OPM %17.56%15.78%15.15%17.66%21.91%19.30%13.88%17.73%19.38%20.35%19.13%
11211588104233148113189494419412
Interest455555655952107112122161178
Depreciation101143193253275304310299357382395
Profit before Tax9659269551,2601,8421,8441,3052,0232,5272,8712,871
Tax %6.22%31.05%18.96%8.77%12.18%8.89%22.84%10.46%12.31%18.03%23.18%
Net Profit9056387741,1491,6181,6801,0071,8112,2162,3532,206
EPS74.6152.7763.6194.26132.57137.6382.31150.21181.14192.54—
Dividend Payout %20.10%24.63%25.15%26.52%22.63%24.70%60.74%26.63%24.84%27.53%—

COMPOUNDED SALES GROWTH

10 Years:
12%
5 Years:
11%
3 Years:
8%

COMPOUNDED PROFIT GROWTH

10 Years:
12%
5 Years:
8%
3 Years:
33%

STOCK PRICE CAGR

10 Years:
12%
5 Years:
6%
3 Years:
12%
1 Year:
-6%

RETURN ON EQUITY

10 Years:
18%
5 Years:
18%
3 Years:
19%
Last Year:
18%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Corporate actions

2026

Aug 7

₹ 5

Rs.10.0000 per share(500%)Final Dividend

2026

Feb 20

₹ 21.50

Rs.43.0000 per share(2150%)Interim Dividend

2025

Aug 8

₹ 4

Rs.8.0000 per share(400%)Final Dividend

2025

Feb 14

₹ 18.50

Interim Dividend

2024

Aug 9

₹ 2.50

Rs.5.0000 per share(250%)Final Dividend

2024

Feb 16

₹ 17.50

Interim Dividend

2023

Aug 10

₹ 5

Rs.10.0000 per share(500%)Final Dividend

2023

Feb 17

₹ 12.50

Interim Dividend

2023

Feb 17

₹ 7.50

2022

Aug 8

₹ 2

Rs.4.0000 per share(200%)Final Dividend

2022

Feb 10

₹ 15

Interim Dividend

2021

Aug 9

₹ 2.50

Rs.5.0000 per share(250%)Final Dividend

2021

Feb 11

₹ 12.50

Interim Dividend

2020

Feb 13

₹ 11

Interim Dividend

2018

Aug 23

₹ 3.50

Rs.7.0000 per share(350%)Final Dividend

2018

Feb 16

₹ 3

Interim Dividend

2017

Aug 31

₹ 4.50

Rs.9.0000 per share(450%)Final Dividend

2016

Nov 23

₹ 3

Rs.6.0000 per share(300%)Interim Dividend

2016

Mar 18

₹ 4.85

Rs.9.7000 per share (485%) Second Interim Dividend

2026

Aug 5

₹ 5

Rs.10.0000 per share(500%)Final Dividend

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital24242424242424242424
Minority Interest115122133148181209390402449529
4,4434,8395,4146,1357,3528,6139,02110,26911,92513,761
6711,0129571,7111,7422,6541,5521,7391,6872,380
Trade Payables7419619629541,0691,1731,1651,7481,9372,244
-1235310414385302-122-69116
Total Liabilities5,8727,0107,5019,01310,41112,76012,45414,06015,95319,054
1,7972,2842,5302,9082,7932,9022,6832,8732,8523,871
Capital Work in Progress299381493363393339310148477138
5534443242613333716224841,8461,869
1,2061,4421,5001,8192,3123,0062,6082,6612,9223,333
121014151716242,2532,4662,979
Cash & Bank3995776621,0921,9902,5792,6171,5791,5631,733
1,6051,8731,9782,5542,5723,5473,5914,0623,8275,131
Total Assets5,8727,0107,5019,01310,41112,76012,45414,06015,95319,054

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
7354691,0318681,6661,5081,9561,9481,9131,963
Cash from Investing-286-357-316-741-999-1,435113-1,008-1,299-1,667
Cash from Financing-13885-37979-272380-1,761-1,145-811-503
47-784-77-55535-205-197-208

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
56.3855.6655.6655.1353.0451.2051.2051.2049.70
8.699.0210.159.409.119.479.9710.1510.41
18.5619.2118.0119.4221.8021.9321.5421.3922.64
Government0.000.000.000.000.000.000.000.000.00
16.3616.1016.1816.0516.0517.4017.3017.2517.25

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-08
Press Release

2026-09-08 - Alkem Laboratories Limited has informed the Exchange regarding a press release dated September 08, 2026, titled "Press Release Alkem Laboratories Limited launches Renocia Exo , India s first patented Ginsenoside Exosome-based hair growth serum".

2026-08-27
Shareholders meeting

2026-08-27 - Alkem Laboratories Limited has informed the Exchange about Intimation under Regulation 30 and 44(3) of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 ( SEBI LODR Regulations ) - Outcome of the 52nd Annual General Meeting of the Company and Disclosure of voting results thereat.

2026-08-20
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-20 - Alkem Laboratories Limited has informed the Exchange about Q1 FY2027 - Earnings Conference Call Transcript

2026-08-17
Shareholders meeting

2026-08-17 - Alkem Laboratories Limited has informed the Exchange regarding Proceedings of the meeting of the equity shareholders of the Company and Scrutinizer s Report on e-voting (remote e-voting and e-voting at the Meeting)

2026-08-15
Copy of Newspaper Publication

2026-08-15 - Alkem Laboratories Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-14
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-14 - Alkem Laboratories Limited has informed the Exchange about Link of Recording

2026-08-14
Trading Window

2026-08-14 - Alkem Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

2026-08-14
General Updates

2026-08-14 - Alkem Laboratories Limited has informed the Exchange about Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ( SEBI LODR Regulations ).

2026-08-14
Investor Presentation

2026-08-14 - Alkem Laboratories Limited has informed the Exchange about Investor Presentation

News

Recent coverage and analyst commentary for ALKEM

Loading news…

🤖

AI Stock Analyst

Alkem Laboratories Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login